What's in KU Leuven's pipeline?

KU Leuven has 12 drugs in our index: 4 marketed, 0 filed, 0 in Phase 3, 4 in Phase 2, 4 in Phase 1.

Which companies overlap with KU Leuven's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, CancerVax Corporation, GERCOR - Multidisciplinary Oncology Cooperative Group, Chiang Mai University, Chiltern Pesquisa Clinica Ltda.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ku-leuven.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

KU Leuven — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KU Leuven pipeline: 4 marketed, 0 filed, 0 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 4 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Mepolizumab Injection [Nucala]	Mepolizumab Injection [Nucala]	marketed	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)	Immunology / Respiratory
Syntocinon (Oxytocin)	Syntocinon (Oxytocin)	marketed	Oxytocin receptor agonist	Oxytocin receptor (OXTR)	Obstetrics and Gynecology
Tiotropium + formoterol/beclometasone	Tiotropium + formoterol/beclometasone	marketed	Long-acting anticholinergic/long-acting beta-2 agonist/inhaled corticosteroid combination	Muscarinic M3 receptor, beta-2 adrenergic receptor, glucocorticoid receptor	Respiratory/Pulmonology
D-cure	D-cure	marketed	Therapeutic cancer vaccine		Oncology

Therapeutic area mix

Immunology / Respiratory · 1
Obstetrics and Gynecology · 1
Oncology · 1
Respiratory/Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 2 shared drug classes
CancerVax Corporation · 1 shared drug class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
Chiang Mai University · 1 shared drug class
Chiltern Pesquisa Clinica Ltda · 1 shared drug class
Ciusss de L'Est de l'Île de Montréal · 1 shared drug class
Centre Leon Berard · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for KU Leuven:

Cite this brief

Drug Landscape (2026). KU Leuven — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ku-leuven. Accessed 2026-06-10.